(Q36102808)

English

Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? (English)

1 reference

Europe PubMed Central

12 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Stefano Oliva

1

1 reference

Europe PubMed Central

12 August 2017

Giovanni Cioffi

2

1 reference

Europe PubMed Central

12 August 2017

Silvia Frattini

3

1 reference

Europe PubMed Central

12 August 2017

Edda Lucia Simoncini

4

1 reference

Europe PubMed Central

12 August 2017

Pompilio Faggiano

5

1 reference

Europe PubMed Central

12 August 2017

Lidia Boccardi

6

1 reference

Europe PubMed Central

12 August 2017

Giovanni Pulignano

7

1 reference

Europe PubMed Central

12 August 2017

Agnese Maria Fioretti

8

1 reference

Europe PubMed Central

12 August 2017

Francesco Giotta

9

1 reference

Europe PubMed Central

12 August 2017

Chiara Lestuzzi

10

1 reference

Europe PubMed Central

12 August 2017

Nicola Maurea

11

1 reference

Europe PubMed Central

12 August 2017

Silvia Sabatini

12

1 reference

Europe PubMed Central

12 August 2017

Luigi Tarantini

13

1 reference

Europe PubMed Central

12 August 2017

Italian Cardio-Oncological Network

14

1 reference

Europe PubMed Central

12 August 2017

publication date

6 June 2012

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

17

1 reference

Europe PubMed Central

12 August 2017

917-924

1 reference

Europe PubMed Central

12 August 2017

7

1 reference

Europe PubMed Central

12 August 2017

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Cardiotoxicity profile of trastuzumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 October 2017

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 July 2018

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

2 July 2018

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399646

23 September 2018

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/22673631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1634/THEONCOLOGIST.2011-0445

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36102808&oldid=1561179944"